Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01799889 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
NCT01799889 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 326 participants.
The verdict
NCT01799889, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies. Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia \[LPL/WM\], small lymphocytic lymphoma \[SLL\], or marginal zone lymphoma \[MZL\]).
Interventions
- DRUG Entospletinib MM
- DRUG Entospletinib SDD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2013-03-14 |
| Est. Completion | 2020-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01799889
The ClinicalTrials.gov registry entry for NCT01799889 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Entospletinib MM is the first listed.
NCT01799889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01799889 about?
NCT01799889 is a clinical study titled "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies". The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies. Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocyti...
What is the current status of trial NCT01799889?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2013-03-14. Estimated completion is 2020-01-30.
What interventions are being tested in trial NCT01799889?
The interventions under investigation include: Entospletinib MM (DRUG), Entospletinib SDD (DRUG).
Who is sponsoring clinical trial NCT01799889?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.